CHF1535 not checked

Chiesi Farmaceutici S.p.A. · Foster 200/6 pMDI

FollowEvery change as it happens, and a Monday email
Stage
in the EU
Next date
Phase 4 trial completes
Trials
1 active
10 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Beclometasone dipropionate, formoterol fumarate (BDP/FF-200/6 µg) administered via pressurised metered-dose inhaler (pMDI) 2 inhalations bid (i.e. 2 inhalations in the morning and 2 inhalations in the evening) for a total of 12 months.”In the company’s words, NCT07666490 on ClinicalTrials.gov
Tested for
Asthma
Main trialPhase 4
“This study will evaluate the effect of triple ICS/LAMA/LABA therapy with a BDP/FF/GB 100/6/12.5 µg on asthma control outcomes relative to ICS/LABA therapy with BDP/FF 200/6 μg in a population with asthma poorly controlled.”In the company’s words, NCT07666490 on ClinicalTrials.gov
Other names
Foster · Fostair · Foster 200/6 pMDI
Copy of
Symbicort (Astrazeneca)Tested side by side with the original in NCT03888131

Other drugs for Asthma

All 58 drugs for Asthma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials10

TrialPhaseCompletesWhat it tests
Phase 4Recruiting 13 Jun 2028 BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])
Phase 4Completed 24 Feb 2023 CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD
Phase 3Completed Mar 2012 BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)
Phase 3Completed 29 Nov 2012 Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients
Phase 3Completed 17 May 2018 TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA
Phase 3Completed 28 May 2018 TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)
Phase 3Completed 6 May 2022 Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)
Phase 2Completed Sep 2012 Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD
Phase 2Completed Apr 2014 A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of "Nexthaler" Dry Powder Inhaler in COPD Patients
Phase 2Completed 16 Oct 2018 Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow CHF1535

Following is part of Solo: you see every change to CHF1535 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in